PF-07799544
Phase 1Small molecule
PfizerPF-07799544 is one of 58 small molecule programs targeting Melanoma. It is currently in Phase 1.
2
Indications
1
Total Trials
1
Active Trials
57
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
ABP 234
AmgenPhase 3
Interferon Alfa
PfizerPhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
Cancervax Vaccine (CANVAXIN)
CCancerVax Corporation
Phase 3
Intron a
Merck & Co.Preclinical
Opdualag
Bristol-Myers SquibbPreclinical
Naporafenib
EErasca, Inc.
Phase 3
Neoadjuvant Nivolumab
TThe Netherlands Cancer Institute
Phase 3
PEG-Intron
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Melanoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PF-07799544. EMBL-EBI & Wellcome Sanger Institute.
- [4]